Company release, 19 May 2022 at 5.35 p.m. (EEST)
The Board of Directors of Nightingale Health Plc has in its meeting on February 2, 2022 and April 14, 2022, approved request of shareholders to convert 730,828 Series A and 280,537 EMP shares of Nightingale Health Plc to Series B shares in accordance with Article 5 in the Articles of Association.
The conversions of Series A shares to Series B shares were registered in the Trade Register on May 19, 2022. The converted shares will be listed on the Nasdaq First North Growth Market Finland marketplace together with the old shares as of May 20, 2022.
The conversions of EMP shares to Series B shares will be registered in the Trade Register on or about May 20, 2022. The converted shares will be listed on the Nasdaq First North Growth Market Finland marketplace together with the old shares as of May 23, 2022.
As a result of conversion of shares, the number of the company’s Series A shares is 20,787,594 and Series B shares is 38,892,100 and EMP shares is 1,238,765, including 36,722 new EMP shares registered on May 10, 2022. The conversion does not affect the total amount of shares which is 60,918,459. The number of votes of the company's shares after the conversion is 246,768,040.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.